Le Lézard
Classified in: Covid-19 virus

Global Linear Motion Systems Market Report 2020-2027: Market to Reach US$9.7 Billion from $6.3 Billion in 2020 - ResearchAndMarkets.com


The "Linear Motion Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Linear Motion Systems Market to Reach US$9.7 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Linear Motion Systems estimated at US$6.3 Billion in the year 2020, is projected to reach a revised size of US$9.7 Billion by 2027, growing at a CAGR of 6.4% over the period 2020-2027.

Single-Axis, one of the segments analyzed in the report, is projected to grow at a 6.8% CAGR to reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Multi-Axis segment is readjusted to a revised 6.2% CAGR for the next 7-year period. This segment currently accounts for a 60.9% share of the global Linear Motion Systems market.

The U.S. Accounts for Over 28.9% of Global Market Size in 2020, While China is Forecast to Grow at a 10% CAGR for the Period of 2020-2027

The Linear Motion Systems market in the U. S. is estimated at US$1.8 Billion in the year 2020. The country currently accounts for a 28.89% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$1.8 Billion in the year 2027 trailing a CAGR of 10% through 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.6% and 5.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR while Rest of European market (as defined in the study) will reach US$1.8 Billion by the year 2027.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

SPAIN

RUSSIA

REST OF EUROPE

ASIA-PACIFIC

AUSTRALIA

INDIA

SOUTH KOREA

REST OF ASIA-PACIFIC

LATIN AMERICA

ARGENTINA

BRAZIL

MEXICO

REST OF LATIN AMERICA

MIDDLE EAST

IRAN

ISRAEL

SAUDI ARABIA

UNITED ARAB EMIRATES

REST OF MIDDLE EAST

AFRICA

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/nbnt6t


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: